One study published in the journal gut, however, detected an association between long-term use of the drug and a twofold greater risk of developing stomach cancer.
The discovery was made by a team of researchers from the University of Hong Kong and University College London found that the risk of developing cancer rose in line with the duration of treatment.
The findings were yielded from a study that looked at a cohort of more than 63,397 adults.
The participants included had been treated with a triple therapy combining PPI, and antibiotics.
Over the course of the study, which took place from 2012 to 2015, a total of 3,271 people took PPI while 21,729 took H2 blocked.
By the end of the follow-up period, a total of 153 people were diagnosed with stomach cancer.
Published at Sun, 16 Jan 2022 04:01:00 +0000
Cancer: The drug linked to a ‘doubled’ risk of cancer – millions prescribed in UK annually
